The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Treating patients with HRMM: the importance of achieving deep and sustained remission
Joseph Mikhael, MD, MeD, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ & International Myeloma Foundation, Studio City, CA, discusses the challenges that remain in treating high-risk multiple myeloma (HRMM). When treating patients with high-risk disease, Dr Mikhael emphasizes the importance of using multi-mechanism combination approaches with a longer duration of treatment to achieve measurable residual disease (MRD) negativity and deep remission. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
